Next, to further investigate the immunoregulatory and prognostic role of DVL2 in response to NAC, we performed a subgroup analysis between DVL2 and different clinical and/or prognostic markers of breast cancer in biopsy and resection specimens of patients who received NAC. This evidence concerns the gene DVL2 and breast carcinoma.